Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation
Study of the Efficacy and Safety of MegaLT Injection for Promoting Platelet Recovery After Umbilical Cord Blood Transplantation
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase inicial 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Xiaoyu Zhu, MD, PhD
- Número de telefone: +86-551-62282931
- E-mail: xiaoyuz@ustc.edu.cn
Estude backup de contato
- Nome: Aijie Huang, MD
- E-mail: huangaijie@mail.ustc.edu.cn
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age ≥18 years, male or female.
- Patients with a definite diagnosis of hematologic malignancy who are undergoing umbilical cord blood transplantation.
- Patients at day 14 after umbilical cord blood transplantation.
- ECOG performance status ≤2.
- Patients who voluntarily agree to participate in this clinical trial, fully understand the study content, and sign the informed consent form.
Exclusion Criteria:
- Patients with relapse of any malignant tumor.
- Pregnant or lactating women.
- Patients with severe infection or severe cardiac, hepatic, pulmonary, renal, neurologic, or metabolic disease.
- Patients with a history of severe thrombotic events or known risk factors for thrombosis. Exception: participants for whom the investigator determines that the potential benefit of study participation outweighs the potential risk of thromboembolic events.
- Patients with uncontrolled infectious disease or other serious diseases, including but not limited to infection such as HIV positivity, congestive heart failure, unstable angina, cardiac arrhythmia, psychosis, social circumstances that would limit compliance with study requirements, or any condition that the treating physician considers may pose unpredictable risks.
- Patients with active hepatitis B or hepatitis C.
- Patients who have previously received organ transplantation or are planning to receive organ transplantation, except for hematopoietic stem cell transplantation.
- Patients who participated in another clinical study and used any investigational drug or device within 30 days before the baseline visit. Participation in observational studies is allowed.
- Patients considered by the investigator to be unsuitable for participation in this clinical trial for any other reason.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: MegaLT Injection
Participants will receive MegaLT Injection by intravenous infusion on day 14 after umbilical cord blood transplantation.
Dose escalation will proceed sequentially from 1×10^6/kg to 2.5×10^6/kg.
Each participant will receive one assigned cell dose; multiple infusions may be considered if necessary according to the protocol.
|
MegaLT Injection is prepared from eligible umbilical cord blood cells through directed expansion and quality control to obtain a megakaryocyte cell product.
Participants will receive MegaLT Injection by intravenous infusion on day 14 after umbilical cord blood transplantation.
The assigned dose will be 1×10^6/kg or 2.5×10^6/kg, with sequential dose escalation from the low-dose level to the high-dose level.
Each participant will receive one assigned cell dose; multiple infusions may be considered if necessary according to the protocol.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to Platelet Engraftment
Prazo: From umbilical cord blood transplantation until documented platelet engraftment or the participant's last platelet assessment, assessed up to 6 months following MegaLT infusion.
|
Platelet engraftment is defined as the first day of 7 consecutive days with platelet count ≥20×10^9/L without platelet transfusion.
|
From umbilical cord blood transplantation until documented platelet engraftment or the participant's last platelet assessment, assessed up to 6 months following MegaLT infusion.
|
|
Platelet Engraftment by Day 28
Prazo: At day 28 after umbilical cord blood transplantation
|
Cumulative incidence of platelet engraftment by day 28 after transplantation, defined as 7 consecutive days with platelet count ≥20×10^9/L without platelet transfusion.
|
At day 28 after umbilical cord blood transplantation
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Platelet Recovery by Day 28
Prazo: At day 28 after umbilical cord blood transplantation
|
Cumulative rate of platelet recovery by day 28 after transplantation, defined as platelet count ≥50×10^9/L for 7 consecutive days without platelet transfusion.
|
At day 28 after umbilical cord blood transplantation
|
|
Time to Platelet Count Thresholds
Prazo: From umbilical cord blood transplantation until documented platelet count recovery at each threshold or the participant's last platelet assessment, assessed up to 6 months following MegaLT infusion.
|
Median time to achieve platelet counts of ≥20×10^9/L, ≥50×10^9/L, and ≥100×10^9/L without platelet transfusion.
|
From umbilical cord blood transplantation until documented platelet count recovery at each threshold or the participant's last platelet assessment, assessed up to 6 months following MegaLT infusion.
|
|
Platelet Transfusion Volume
Prazo: From MegaLT Injection to 4 weeks after injection
|
Total amount of platelet transfusion received by participants within 4 weeks after MegaLT Injection.
|
From MegaLT Injection to 4 weeks after injection
|
|
Neutrophil Engraftment by Day 28
Prazo: At day 28 after umbilical cord blood transplantation
|
Cumulative incidence of neutrophil engraftment by day 28 after transplantation, defined as an absolute neutrophil count ≥0.5×10^9/L for 3 consecutive days.
|
At day 28 after umbilical cord blood transplantation
|
|
Megakaryocyte Level in Bone Marrow
Prazo: At 4 weeks after MegaLT Injection
|
Megakaryocyte level assessed by bone marrow smear 4 weeks after MegaLT Injection.
|
At 4 weeks after MegaLT Injection
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse Events
Prazo: From MegaLT Injection to 6 months after injection
|
Incidence of adverse events after MegaLT Injection, including clinical symptoms and laboratory abnormalities.
Adverse events will be assessed according to the Common Terminology Criteria for Adverse Events version 5.0 when applicable.
|
From MegaLT Injection to 6 months after injection
|
|
Bleeding Events
Prazo: From MegaLT Injection to 6 months after injection
|
Incidence of bleeding events after MegaLT Injection, assessed using the WHO bleeding assessment scale.
|
From MegaLT Injection to 6 months after injection
|
|
Transplant-Related Complications and Mortality
Prazo: From umbilical cord blood transplantation to 100 days after transplantation
|
Incidence of transplant-related complications and transplant-related mortality within 100 days after umbilical cord blood transplantation.
|
From umbilical cord blood transplantation to 100 days after transplantation
|
|
Graft-Versus-Host Disease
Prazo: From MegaLT Injection to 6 months after injection
|
Incidence and severity of acute graft-versus-host disease and chronic graft-versus-host disease after MegaLT Injection.
|
From MegaLT Injection to 6 months after injection
|
|
Severe GVHD-Free, Relapse-Free Survival
Prazo: From MegaLT Injection to 6 months after injection
|
Survival without severe graft-versus-host disease or relapse after MegaLT Injection.
|
From MegaLT Injection to 6 months after injection
|
|
Thromboembolic Events
Prazo: From MegaLT Injection to 6 months after injection
|
Incidence and severity of thromboembolic events after MegaLT Injection, including deep vein thrombosis and pulmonary embolism.
Relevant indicators such as D-dimer will be dynamically monitored.
|
From MegaLT Injection to 6 months after injection
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- MegaLT-2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .